Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study

Martin W. Bergmann1*, MD, PhD, FESC; Hüseyin Ince2, MD; Stephan Kische3, MD; Thomas Schmitz4, MD; Felix Meincke5, MD; Boris Schmidt6, MD; David Foley7, MB, BCh, PhD; Timothy R. Betts8, MD; Marek Grygier9, MD; Alexey V. Protopopov10, MD; Kenneth M. Stein11, MD; Lucas V.A. Boersma12, MD